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Abstract
Background: Human papillomavirus (HPV) has been associated with several disorders of the genital tract, skin and
oropharynx. The aims of our study were to evaluate the prevalence of HPV infection in women between 15 and 54
years of age in North Sardinia, Italy, to identify the prevalence of High Risk - Human papillomaviruses (HR-HPV)
genotypes and to establish a correlation between molecular and cytological results.
Methods: From 2007 to 2009 we consecutively enrolled women aged 15-54 years admitted to public and private
outpatient settings. All the participants filled in a questionnaire about the socio-cultural state, sexual activity and
awareness about HPV. 323 cervical specimens were tested for HPV-DNA and HPV genotypes with INNO-LiPA HPV
Genotyping CE Amp kit. Samples showing positivity to some HPV genotypes were re-tested using “in house”
quantitative Real-Time PCR assays.
Results: Overall HPV-DNA positivity was detected in 35.9% of the women. The prevalence of HR-HPV infection among
HPV positive samples was 93.1% with a specific prevalence of HPV 16, 51, 31, 53 and 18 of 54.3%, 37.9%, 10.3%, 6.9%
and 5.2%, respectively. Co-infection with any HPV, HR-HPV, LR-HPV and HR/LR-HPV type was 18.3%, 14.9%, 0.9% and
2.5%, respectively; HPV 16/51 co-infection was detected in 64.6% of the HR-HPV co-infection group. The most frequent
HPV-genotypes detected were 16 (32.5%) and 51 (22.7%). Among the 57 patients harboring mono-infection the most
prevalent HPV genotypes were 16 (38.6%) and 31(10.5%). A multivariate analysis identified a statistical significant
association between HPV infection and age and between HPV infection and previous sexual transmitted diseases.
A statistically significant association between cytological cervical lesions and generic HPV exposure was identified.
Conclusions: To our knowledge, this is the first survey evaluating the prevalence of HPV infection in Northern
Sardinia and drawing attention to the unusual high proportion of genotype HPV 51. Given the recent
implementation of a widespread immunization program with vaccines not containing HPV 51, it has been relevant
to prove the high prevalence of this HPV genotype from the start of the vaccination campaign, in order to avoid
in the future attributing to the vaccination program a possible selection effect (HPV replacement).
Background
Human papillomaviruses (HPVs), double stranded DNA
viruses belonging to family papillomaviridae,a r eh i g h l y
epitheliotropic viruses and have been associated with
various cutaneous or mucosal clinical manifestations
ranging from benign hyperplastic epithelial proliferative
innocuous lesions (warts, papillomas) to cancer of the
genital tract, skin, oropharynx [1,2]; in particular, they
have been recognized as causative agents in the develop-
ment of cervical cancer [3].
Several genotypes are defined as high-risk (HR-HPV)
being associated with a comparatively high risk for inva-
sive neoplasia; furthermore, they are sub-classified as car-
cinogenic (types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58
and 59), probably carcinogenic (type 68) and possibly * Correspondence: piana@uniss.it
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any medium, provided the original work is properly cited.carcinogenic (types 26, 30, 34, 53, 66, 67, 69, 70, 73, 82, 85
and 97) to humans [4].
HPV types 16 and 18 account for approximately 70%
of cervical cancer cases worldwide with other high-risk
types such as HPV-45, HPV-31, HPV-33 and HPV-52
accounting for the majority of the remaining cervical
malignancies [5]. HPV “low-risk” types (LR-HPV),
mainly HPV-6 and HPV-11, are rarely detected in high-
grade cervical lesions but cause the majority of anogen-
ital warts [6].
The link between HPV infection and cervical cancer
has given impetus to the development of prophylactic
vaccines against the most common HR-HPV types; in
parallel, interest has been raised to determine age speci-
fic burden of HPV infection and to identify the major
genotypes supporting infection and diseases in different
countries.
Heterogeneous distribution of HPV prevalence and gen-
otypes has been described worldwide [7].
In Italy, a recent cross-sectional study on HR-HPV
infection showed an overall prevalence of 14.8% country-
wide, without significant differences among geographical
regions [8].
However, another recent study [9] carried out in the
South of Sardinia, Italy, showed that 31% of the tested
women were HPV-positive; single or multiple infections
sustained by HPV-16 or HPV-18 represented 43.5% of all
HPV infections.
Furthermore, another interesting finding from previous
Italian studies was the relatively high prevalence observed
of HPV-51 [8,10-12]. It is expected that the implementa-
tion and scale-up of the national immunization HPV strat-
egy, by the use of one of the two commercially available
vaccines, Cervarix™ and Gardasil
® in adolescents aged 12
years since 2007 could modify the epidemiological
scenario.
The aims of our study were to evaluate the prevalence of
HPV infection in women between 15 and 54 years of age
in North Sardinia, Italy, to identify the prevalence of HR-
HPV genotypes and to establish a correlation between
molecular and cytological results.
Methods
Study population
In Sardinia, Italy, the average coverage of PAP-test in
women aged 25-64 years is 49.3%, of which 24.9% on
voluntary basis [13,14]. During the study period
(November 2007 - January 2009) we consecutively
enrolled women aged between 15 and 54 years admitted
to public and private outpatient settings located in the
town of Sassari, Northern area of Sardinia, where cervi-
cal screening, unlike other Italian geographical areas,
was performed on a voluntary basis and not as part of a
prevention program [14-17].
Personal data have been treated in compliance with
the Law Decree No. 196/2003, article 24 (Code for the
protection of personal data). This study, for which a
written consent from each enrolled patient or her rela-
tives was obtained, was formerly approved by the Ethical
Committee of the Azienda Sanitaria Locale n°1 of Sas-
sari (PN-132) on June 18, 2007.
Statistical analysis
A power of 80% and a level of statistical significance of
5% was necessary to determine the sample size in order
to detect a difference between proportions: on the basis
of the female population aged 15-54 in Sassari in 2006
(N = 37,353 women), the eligible (i.e., 24.9% of the total
referring to specialized centers on a voluntary basis)
population was 9,301 women. Since the prevalences of
HPV-positivity and of HPV-16, estimated in an Italian
city, (8.8% and 2.87%, respectively [22]), the overall sam-
ple size for any HPV infection was 318 individuals and
the sample size for each planned age group (i.e., 15-24,
25-34, 35-44, 45-54 years) for the most frequent HPV
type (i.e., 2.87% for HPV16) was 43. Therefore, at least
50 individuals were expected to be enrolled in every
group.
Difference between proportions were compared via z-
test. Categorical variables were compared by Chi-squared
test and continuous variables by t-test or Mann-Whitney
test. Logistic regression analysis of the association between
HPV infection in cervical lesions with potential covariates
was performed.
Ap - v a l u eo f≤0.05 was considered statistically signifi-
cant. Data were collected on standardised e-forms and
analysed using Stata 9.0 (StataCorp, Stata Statistical
Software Release 9, College Station, TX, USA, 2005).
Sample collection
Cervical specimens were collected with Cervex-brush
and suspended in a 20 ml preservation solution, Preserv-
Cyt transport medium (ThinPrep Pap Test; Cytyc Cor-
poration, Boxborough, Mass.).
INNO-Lipa HPV Genotyping test (Innogenetics)
The DNA extraction was performed following the proto-
col described in the High Pure Viral Nucleic Acid kit from
Roche Diagnostics. HPV DNA amplification was carried
out with INNO-LiPA HPV Genotyping CE Amp kit [18],
which targets a 65-bp fragment of the L1 open reading
frame; in particular, DNA is PCR amplified using biotiny-
lated primers, deoxynucleotide triphosphates (dNTPs),
thermostable DNA polymerases.
The sample mixture is heated in order to separate the
two strands of the DNA helix and expose the target
sequences to the primers. After 40 cycles, a multi-ampli-
fied biotinylated target sequence is obtained.
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tion by the INNO-line probe assay (INNO-LiPA HPV
Genotyping Extra). The diagnostic test contains probes for
28 anogenital HPV genotypes (HPV 6, 11, 16, 18, 26, 31,
33, 35, 39, 40, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 66, 68,
69, 70, 71, 73, 74, 82). The hybridization steps were carried
out following the INNO-LiPA kit instruction. The oligo-
nucleotide probes, together with 3 controls, were immobi-
lized in parallel lines on nitrocellulose membrane strips by
the supplier. After hybridization of the PCR product to the
probes on the strip under stringent conditions, followed
by stringent washing, the hybrids were detected by alkaline
phosphatase/streptavidin conjugate; reaction with a sub-
strate (5-bromo-4-chloro-3-indolylphosphate and nitro-
blue tetrazolium) results in a purple precipitate at the
positive probe lines. After drying, the strips were inter-
preted visually by using the INNO-LiPA HPV genotyping
v2 interpretation chart.
Samples found to be positive for HR-HPV genotypes 16,
18, 31, 45, 51 and 52 by INNO-LiPA were further con-
firmed by the previously described “in-house” Real-Time
quantitative TaqMan PCR assays [19-21]. Amplification
was performed using using TaqMan technology and ABI
Prism device (7900 SDS; Applied Biosystems, Forster City,
CA). All reactions were optimized to obtain the best
amplification kinetics under the same cycling conditions
(denaturation at 95°C for 15 min, followed by 40 cycles of
denaturation at 95°C for 15 s and annealing/extension at
60°C for 60 s) and composition of the reaction mixture.
Detection and quantification of CCR5 was used to quan-
tify human genomic DNA in each sample and to normal-
ize the viral load [20] and viral load expressed as copies
number for 10
4 cells.
Results
The characteristics of the population studied are described
in table 1. From November 2007 to January 2009, 323
cytological samples were collected from women whose age
ranged from 15-54 years (median; InterQuartile Range: 37;
28-44). The age of the majority of enrolled individuals
(199/323, 61.6%) ranged from 25 to 44 years; most of
them were Caucasians (309/323, 95.7%), with a high edu-
cational level (high school or academic degree: 244/322,
75.8%).
More than half of the enrolled women (57.9%) were
married (165 currently married while 22 in the recent
past), 50% were smokers and/or ex-smokers, 55.0% (177/
323) were nulliparous, most of them taking oral contra-
ceptives. Mean (SD) age of first sexual intercourse was
18.7 (3.3) years.
Number of lifetime sexual partners was at least 2 in more
than 50%: 37.6% (121/323) and 19.3% (62/323) had had 2-3
and 4-9 sexual partners, respectively; 10.5% (34/323) had
had a new sexual partner in the last three months.
Twenty-eight percent (89/318) of the enrolled indivi-
d u a l ss t a t e dt h a tt h e yh a dn e v e ru s e dc o n d o md u r i n g
their sexual relationships; 17.8% (56/315) had been
affected by sexually transmitted diseases: about half of
them being infected by HR-HPV genotypes (27/56,
48.2%) versus about one-third of those without a history
of sexually transmitted diseases (78/259, 30.1%).
The proportion of women (191/318, 60.1%), who had
had a Pap test in the last three years, was significantly
higher than the national average (39.8%) [15-17].
Table 2 reports the prevalence of high and low risk HPV
types stratified by age groups and cytological results. The
prevalence of HPV infection was 35.9% (116/323),
although it showed a significant age-related decrease
(53.9%, 41.4%, 32.1% and 22.2% in those whose age ranged
from 15-24, 25-34, 35-44 and 45-54 years, respectively.
Slope -0.10, P for trend < 0.001); a similar trend was
observed for those infected by HR-genotypes: prevalence
of HR-HPV infection was 53.9% between 15-24 years,
35.6% between 25-34 years, 31.3% between 35-44 years
and 19.4% in those aged more than 44 years (Slope -0.10,
P for trend < 0.001).
From the 116 HPV positive specimens, 194 HPV geno-
types were detected (Figure 1): 162/194 (83.5%) HR-HPV
genotypes and 32/194 (16.5%) LR-HPV genotypes.
Overall, the most frequent HPV-genotypes detected
were 16 (63/194, 32.5%), 51 (44/194, 22.7%), 6 (15/194,
7.7%), 31 (12/194, 6.2%) and 53 (8/194, 4.1%).
Out of 323 women, 108 (33.4%) were positive for at
least one HR-HPV genotype. The prevalence of HR-HPV
infection among the HPV positive samples was 93.1%
(108/116) with a specific prevalence of HPV 16, 51, 31,
53 and 18 of 54.3% (63/116), 37.9% (44/116), 10.3% (12/
116), 6.9% (8/116) and 5.2% (6/116), respectively. The
most frequent LR-HPV genotypes among the HPV posi-
tive samples were type 6 (15/116, 12.9%) and type 11 (6/
116, 5.2%).
Co-infection with any HPV, HR-HPV, LR-HPV and HR/
LR-HPV type was detected in 59/323 (18.3%), 48/323
(14.9%), 3/323 (0.9%) and 8/323 (2.5%), respectively; HPV
16/51 co-infection was detected in 64.6% of the HR-HPV
co-infection group. Overall, the prevalence of the two
most frequent types (i.e., HPV16 and 51) was 19.8% and
13.8%, respectively. The observed proportion of HP16/51
co-infection was 9.7%, whereas the expected one was 2.7%
(p < 0.001). No HPV16/18 co-infection was detected.
Among the 57 patients harboring mono-infection the
most prevalent HPV genotypes were 16 (38.6%), 31
(10.5%), 53 (8.8%) and 51 (7.0%).
The specificity of INNO-LiPA positive samples for HR-
HPV genotypes 16, 18, 31, 45, 51 and 52 was further con-
firmed by previously described “in-house” Real-Time
quantitative TaqMan PCR assays [19-21]. All retested
positive samples were confirmed to harbour the HR-HPV
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cificity in genotype detection of this assay. Furthermore
overall viral loads detected by the quantitative “in-house”
Real-Time PCR assays for the studied HR-HPVs were
found to range from 1 to 34750 copies/10
4 cells with med-
ian values for the two most prevalent HPV genotypes 16
and 51 being 962 and 2055 copies/10
4 cells respectively.
Out of 303 women with cytological assessment, 242
(79.9%) showed negative cytology while 32 (10.6%), 25
(8.3%) and 4 (1.3%) showed a pattern of atypical cells of
undetermined significance (ASCUS), a low-grade of
squamous intraepithelial lesion (LSIL) and a high-grade
of squamous intraepithelial lesion (HSIL), respectively
(Table 2).
Univariate logistic regression analysis showed that HPV
infection was significantly associated with previous sexual
transmitted diseases (OR: 2.68; P = 0.001; 95% CI: 1.48 -
4.82), number of sexual partners (OR: 1.30; P: 0.033; 95%
CI: 1.02 - 1.66), number of sexual partners in the last
three months (OR: 1.98; P: 0.018; 95% CI: 1.13 - 3.47),
age (OR: 0.95; p < 0.001; 95% CI: 0.93 - 0.98) and onset
of sexual activity (OR: 0.89; P = 0.005; 95% CI: 0.82 -
0.97), whereas, the multivariate analysis identified a sta-
tistical significance only for age and previous sexually
transmitted diseases.
Although a statistically significant association between
cytological cervical lesions and generic HPV exposure
(OR: 2.77; P = 0.010; 95% CI: 1.27 - 6.05) was identified,
Table 1 Epidemiological and clinical characteristics of the enrolled individuals.
Characteristics Total
sample
HPV-
individuals
HPV+
individuals
HR/HPV+
individuals
Median (IQR) age 37 (28-44) 38 (30-45) 32 (25-39)** 32 (24-38.5)
Age, n (%) 15-24 52 (16.1) 24 (11.6) 28 (24.1)** 28 (25.9)
25-34 87 (26.9) 51 (24.6) 36 (31.0) 31 (28.7)
35-44 112 (34.7) 76 (36.7) 36 (31.0) 35 (32.4)
45-54 72 (21.3) 56 (27.1) 16 (13.8)** 14 (13.0)
Educational level, n (%) Primary
school
5 (1.6) 5 (2.4) - -
Middle school 73 (22.7) 47 (22.7) 26 (22.6) 23 (21.5)
High school 160 (49.7) 95 (45.9) 65 (56.5) 61 (57.0)
University 84 (26.1) 60 (29.0) 24 (20.9) 23 (21.5)
Married or divorced, n (%) 187 (58.1) 133 (64.6) 54 (46.6)** 51 (47.2)
Smoking habit, n (%) Smoker 88 (27.3) 53 (25.7) 35 (30.4) 33 (30.8)
Non smoker 160 (49.7) 104 (50.5) 56 (48.7) 52 (48.6)
Ex smoker 73 (22.7) 49 (23.8) 24 (20.9) 22 (20.6)
Nulliparity, n (%) 177 (55.0) 102 (49.5) 75 (64.7)** 70 (64.8)
Oral contraceptive use, n (%) 252 (78.5) 155 (75.6) 97 (84.4) 90 (84.1)
Mean (SD) age at first sexual intercourse 18.7 (3.3) 19.1 (3.4) 18.0 (2.9)** 18.0 (2.9)
No of partners since first sexual intercourse, n
(%)
0 4 (1.2) 4 (1.9) - -
1 112 (34.8) 76 (36.9) 36 (31.0) 35 (32.4)
2-3 121 (37.6) 81 (39.3) 40 (34.5) 37 (34.3)
4-9 62 (19.3) 31 (15.1) 31 (27.7)* 28 (25.9)
>9 23 (7.1) 14 (6.8) 9 (7.8) 8 (7.4)
No of new partners in the last 3 months, n (%) 0 282 (87.6) 189 (91.8) 93 (80.2)** 86 (79.6)
1 34 (10.6) 13 (6.3) 21 (18.1)** 20 (18.5)
>1 6 (1.9) 4 (1.9) 2 (1.7) 2 (1.9)
Use of condom, n (%) Never 89 (27.8) 55 (26.8) 34 (30.1) 33 (31.4)
Past 59 (18.4) 37 (18.1) 22 (19.5) 19 (18.1)
Current 170 (53.1) 113 (55.1) 57 (50.4) 53 (50.5)
History of Sexually Transmitted Diseases, n (%) 56 (17.7) 25 (12.4) 31 (27.4)** 27 (25.7)
Compliance to PAP test in the last 3 years, n (%) 191 (60.1) 119 (57.8) 72 (64.3) 67 (64.4)
Sample, n (%; 95% CIs) 323 207 (64.1; 57.6-
70.6)
116 (35.9; 30.7-
41.1)
108 (33.4; 28.3-
38.5)
IQR: InterQuartile Range
SD: Standard Deviation
CIs: Confidence Intervals
Comparison vs HPV - individuals: *p < 0.05, **p < 0.01
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Page 4 of 8Table 2 Prevalence of high- and low-risk HPV types stratified by age groups and cytological results.
HPV 16 HPV 18 HPV 51 Other than HPV
16 and 51 HR
types
Nearest non-
vaccine types
(31, 33, 45, 52,
58)
HR types LR types Any HPV type Mono-infection Co-infection
with HR and/or
LR types
n (%) 95%
CIs
n
(%)
95%
CIs
n (%) 95%
CIs
n (%) 95%
CIs
n (%) 95%
CIs
n (%) 95%
CIs
n (%) 95%
CIs
n (%) 95%
CIs
n (%) 95%
CIs
n (%) 95%
CIs
Age 15-24 11
(21.2)
10.1-
32.3
5
(9.6)
1.6-
17.6
7
(13.5)
4.2-
22.8
15
(28.9)
16.6-
41.2
7
(31.8)
12.3-
51.3
28
(53.9)
40.4-
67.5
10
(19.2)
8.3-
29.7
28
(53.9)
40.4-
67.5
12
(23.1)
11.7-
34.6
16
(30.8)
18.3-
43.4
25-34 19
(21.8)
13.1-
30.5
1
(1.2)
-1.1-
3.5
11
(12.6)
5.6-
19.6
16
(18.4)
10.3-
26.5
8
(36.4)
16.3-
56.5
31
(35.6)
25.5-
45.7
10
(11.5)
4.4-
17.6
36
(41.4)
31.1-
51.8
20
(23.0)
14.2-
31.8
16
(18.4)
10.3-
26.5
35-44 25
(22.3)
14.6-
30.0
0
(0.0)
0.0-
0.0
20
(17.9)
10.8-
25.0
7 (6.3) 1.8-
10.8
5
(22.7)
5.2-
40.2
35
(31.3)
22.7-
39.9
5 (4.5) 0.6-
8.2
36
(32.1)
23.5-
40.8
16
(14.3)
10.8-
25.0
20
(17.9)
10.8-
25.0
45-54 8
(11.3)
4.0-
18.6
0
(0.0)
0.0-
0.0
6 (8.3) 2.0-
15.0
7 (9.7) 2.9-
16.5
2
(9.1)
-2.9-
21.1
14
(19.4)
10.3-
28.5
3 (4.2) 0.2-
10.8
16
(22.2)
12.6-
31.8
9
(12.5)
2.9-
16.5
7 (9.7) 2.9-
16.5
PAP-
test
Normal 48
(19.9)
4.9-
49.0
3
(1.2)
-0.2-
2.6
32
(13.2)
8.9-
17.5
21
(8.7)
5.2-
12.3
13
(5.4)
2.6-8.3 84
(34.7)
28.7-
40.7
18
(7.4)
4.2-
10.8
78
(32.2)
26.3-
38.1
42
(17.4)
12.6-
22.2
41
(16.9)
12.2-
21.6
ASCUS 4
(12.5)
1.0-
24.0
2
(6.3)
-2.1-
14.7
2 (6.3) -2.1-
14.7
9
(28.1)
12.4-
43.6
4
(12.5)
1.0-
24.0
9 (28.1) 12.5-
43.7
5
(15.6)
2.6-
27.4
14
(43.8)
26.6-
61.0
5
(15.6)
3.0-
28.2
7
(21.9)
7.6-
36.2
LSIL 6
(24.0)
7.3-
40.7
1
(4.0)
-3.7-
11.7
4
(16.0)
1.6-
30.4
4
(16.0)
1.6-
30.4
3
(12.0)
0.7-
24.7
9 (36.0) 17.2-
54.8
5 (20) 4.3-
35.7
13
(52.0)
32.4-
71.6
6
(24.0)
7.3-
40.7
7
(28.0)
10.4-
45.6
HSIL 2
(50.0)
1.0-
99.0
0
(0.0)
0.0-
0.0
2
(50.0)
1.0-
99.0
1
(25.0)
-17.4-
67.4
1
(25.0)
-17.4-
67.4
3
(75.0)
32.5-
100.0
0 (0.0) 0.0-
0.0
4
(100.0)
1-1 1
(25.0)
-17.4-
67.4
2
(50.0)
1.0-
99.0
All screened
sample
63
(19.5)
15.3-
23.9
6
(1.9)
0.4-
3.4
44
(13.6)
9.9-
17.5
45
(13.9)
10.2-
17.8
22
(6.8)
-3.7-
17.4
108
(33.4)
28.3-
38.5
28
(8.7)
5.6-
11.8
116
(35.9)
30.7-
41.1
57
(17.7)
13.5-
21.9
59
(18.3)
13.8-
22.2
CIs: Confidence Intervals
ASCUS: Atypical Squamous Cells of Undetermined Significance
LSIL: Low-grade Squamous Intra-epithelial Lesion
HSIL: High-grade Squamous Intra-epithelial Lesion
HR: High-Risk genotype
LR: Low-Risk genotype
P
i
a
n
a
e
t
a
l
.
B
M
C
P
u
b
l
i
c
H
e
a
l
t
h
2
0
1
1
,
1
1
:
7
8
5
h
t
t
p
:
/
/
w
w
w
.
b
i
o
m
e
d
c
e
n
t
r
a
l
.
c
o
m
/
1
4
7
1
-
2
4
5
8
/
1
1
/
7
8
5
P
a
g
e
5
o
f
8this was not confirmed for infections due to HPV 16, 18
and 51.
Discussion
Our results highlight that the prevalence of HPV cervical
infection in Northern Sardinia (35.9%) is almost similar to
that estimated in other Italian geographical areas (33% and
31% in Puglia region and in the province of Cagliari,
respectively) [9,22], but higher than that found in other
parts [23]. It was recognized an age-related decrease of
HPV prevalence, mostly evident in those subjects infected
by HR-HPV genotypes.
One of the striking findings is the high prevalence of
HPV 16/51 coinfections; our study was aimed at study-
ing HPV infection’s prevalence, although it would have
been interesting to follow-up co-infected individuals in
order to assess the association between cervical neo-
plasm and multiple infections.
A high frequency of HPV-16 infection, followed by
HPV-51 infection, was observed in our survey, whereas
t h ep r e v a l e n c eo fH P V - 1 8i n f ection is significantly
lower than that identified in the Southern Sardinian
areas [9].
It is remarkable the observed high relative frequency
of HPV-51 infection together with other HR- and LR-
HPV types: this could be an epidemiological feature of
Northern Sardinia, confirming data described in several
recent Italian cross-sectional studies (12% -15.3%) where
it is frequently detected with other HR-HPV types and
in patients affected by CIN 2 [10].
Logistic regression analysis showed a statistically sig-
nificant association between cytological cervical lesions
and HPV infection (OR: 2.77; p = 0.010), but such asso-
ciation was not confirmed with HPV 16, 18 and 51
infections, probably due to the low statistical power of
the study, that was set up using the estimated preva-
lence of HPV-16 infection.
Several variables have been found to be significant
associated with HPV infection both positively (previous
sexually transmitted diseases, number of sexual partners,
number of sexual partners in the last three months) and
negatively (age, onset of sexual activity), confirming the
Figure 1 HPV genotype distribution in the Sardinian cohort.
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Page 6 of 8validity of the immunization strategy, mainly aimed at
girls aged 12 years, before starting of sexual activity.
The successful nationwide implementation of the HPV
vaccination program in Italy will probably change the fre-
quency of the most prevalent genotypes, decreasing the
prevalence of the current genotypes and increasing the
possibility of HPV replacement following vaccination, as
already described for several bacterial infections [24].
E v e ni ft h ep r o b a b i l i t yo fo c c u r r e n c eo ft h a tc o n d i t i o n
was deemed low until now [25], it was recently observed
a competitive advantage of some HPV genotypes over
other genital HPV types in the unvaccinated population
[26]. Therefore, HPV genotype prevalence should be
monitored for type replacement before, during and after
mass vaccination. Surveillance of HPV infections through
molecular methods could represent an important mean
for the development of new primary and secondary pre-
vention strategies, such as new vaccines targeted to geno-
types which might replace those previously prevalent;.
Furthermore, surveillance programs can allow the detec-
tion of local differences in prevalence of HPV genotypes
not covered by the current vaccines, such as HPV-51 in
North Sardinia.
Conclusions
To our knowledge, this is the first survey addressing the
prevalence of HPV infection in Northern Sardinian popu-
lation and it draws attention to the unusual high preva-
l e n c eo fg e n o t y p eH P V5 1i nt h is territory. Even if some
studies in other regions have already described a high
frequency of this HR HPV type, HPV 51 continues to
r e m a i nar a r eg e n o t y p ea l m o s te v e r y w h e r e .G i v e nt h e
recent implementation in Italy of a widespread vaccina-
tion program with prophylactic HPV vaccines not con-
taining HPV 51, it is important to emphasize the high
prevalence of this “atypical” HPV genotype from the start
of the vaccination campaign, in order to avoid attributing
to the vaccination program in the future a possible selec-
tion effect with consequent HPV replacement. Therefore,
our results confirm the need of pre and post-vaccine
extensive surveillance in order to better understand the
effectiveness of vaccination.
However, the precision of our study, as displayed by the
wide confidence intervals, may be limited by the small
sample size. Therefore, for some low prevalent genotypes
the statistical power was low and the possibility that the
true prevalence may be different than the observed one
cannot be excluded. Moreover, we know that the results
of the study may be limited because of the characteristics
of the screening adopted in Northern Sardinia so far. In
fact, a voluntary based access instead of a systematic one
may have selected those patients with higher prevalence of
symptoms and it may explain the higher HPV prevalence
observed. However, the potential selection bias might be
not so influent, since no significant differences between
positive and negative women were detected in terms of
compliance to the PAP test in the last 3 years, as reported
in Tab. 1. Therefore, this study should be able to give a
reliable picture of the epidemiological HPV type pattern of
infection, at the beginning of the vaccination campaign in
the local population.
In conclusion, this study has confirmed the high preva-
lence of HPV infection in our region, as previously
reported for Southern Sardinia, moreover highlighted the
possible role of uncommon genotypes such as HPV-51.
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